Pfenex is utilizing Pfēnex Expression Technology™ to build a comprehensive portfolio of biosimilar molecules. No advantages are gained by simply repeating an innovator’s protein expression and bioprocess strategy that may have been developed more than 20 years ago. Pfenex applies its parallel processing, toolbox approach to strain development to arrive at a highly advantaged expression strain and bioprocess. Capitalizing on the cost effectiveness of the Pfenex's technology-based processes and the proven ability to rapidly identify a robust production strain, Pfenex is becoming a global leader in biosimilar development.
Pfenex currently has nine biosimilar molecules in development. We are currently seeking co-development partners for our unpartnered molecules, and on other new biosimilar programs.